The high efficacy, favorable safety profiles and minimal drug-drug interactions between IDH inhibitors and venetoclax in IDH1/2-mutant AML, have generated interest in combining them together to test synergy and improve outcomes. Here, IDH2 is linked to acute myeloid leukemia.